top of page
  • LinkedIn

Stefanos Theoharis, PhD

Extensive Cell and Gene Therapy Experience

Career Highlights

  • 20 years of broad experience in the cell and gene therapy space, business development, program management, manufacturing and basic research

  • Currently Chief Business Officer for Bone Therapeutics, a Belgium-based company, developing specialized cell therapies for orthopaedic disorders, whilst working closely with clients in the CAR/TCR field and vivo gene therapy on their product development, licensing and manufacturing strategy

  • Previously SVP Corporate Development at Cell Medica (now Kuur Therapeutics), where he led the transactions behind strategic alliances with the Baylor College of Medicine and University College London, the acquisition of Delenex Therapeutics and the licensing of WT1 and broad partnership with the Cell and Gene Therapy Catapult (UK)

  • Has served as Chief Business Officer for apceth, responsible for business development and project management for the company’s contract development and manufacturing organization (CDMO) activities (now a part of Hitachi Chemical Advanced Therapeutics Solutions, LLC) and for its in-house genetically modified mesenchymal stem cell (MSC) pipeline

  • Director of Emerging Technologies Partnering at Roche


  • PhD in gene therapy and immunology and postdoctoral research experience at Imperial College London

  • MSc in Molecular Medicine at Imperial College London

bottom of page